nach oben

Erschienen in:

01.11.2013 | Research Article

Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer

verfasst von: A. Innamaa, L. Jackson, V. Asher, G. van Schalkwyk, A. Warren, A. Keightley, D. Hay, A. Bali, H. Sowter, R. Khan

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Aberrant expression of potassium (K⁺) channels contributes to cancer cell proliferation and apoptosis, and K⁺ channel blockers can inhibit cell proliferation. TREK-1 and -2 belong to the two-pore domain (K2P) superfamily. We report TREK-1 and -2 expression in ovarian cancer and normal ovaries, and the effects of TREK-1 modulators on cell proliferation and apoptosis.

Methods

The cellular localisation of TREK-1 and -2 was investigated by immunofluorescence in SKOV-3 and OVCAR-3 cell lines and in cultured ovarian surface epithelium and cancer. Channel expression in normal ovaries and cancer was quantified by western blotting. Immunohistochemical analysis demonstrated the association between channel expression and disease prognosis, stage, and grade. TREK-1 modulation of cell proliferation in the cell lines was investigated with the MTS-assay and the effect on apoptosis determined using flow cytometry.

Results

Expression was identified in both cell lines, ovarian cancer (n = 22) and normal ovaries (n = 6). IHC demonstrated positive staining for TREK-1 and -2 in 95.7 % of tumours (n = 69) and 100 % of normal ovaries (n = 9). A reduction in cell proliferation (P < 0.05) was demonstrated at 96 h in SKOV-3 and OVCAR-3 cells incubated TREK-1 modulating agents. Curcumin caused a significant reduction in early apoptosis in SKOV-3 (P < 0.001) and OVCAR-3 (P < 0.0001) cells and a significant increase in late apoptosis in SKOV-3 (P < 0.01) and OVCAR-3 cells (P < 0.0001).

Conclusions

TREK-1 and -2 are expressed in normal ovaries and ovarian cancer. TREK-1 modulators have a significant effect on cell proliferation and apoptosis. We propose investigation of the therapeutic potential of TREK-1 blockers is warranted.

Cancer Research UK: Ovarian cancer statistics. [Internet]. [Cited: 2012, December]. Available from: http://info.cancerresearchuk.org/cancerstats/keyfacts/ovarian-cancer/uk-ovarian-cancer-statistics.

Ozols RF. Challenges for chemotherapy in ovarian cancer. Ann Oncol. 2006;17(Suppl 5):181–7.CrossRef

Ding XW, Yan JJ, An P, Lu P, Luo HS. Aberrant expression of ether a go-go potassium channel in colorectal cancer patients and cell lines. World J Gastroenterol. 2007;13:1257–61.PubMed

Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, et al. Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 2003;3:297–302.PubMedCrossRef

Voloshyna I, Besana A, Castillo M, Matos T, Weinstein IB, Mansukhani M, et al. TREK-1 is a novel molecular target in prostate cancer. Cancer Res. 2008;68:1197–203.PubMedCrossRef

Felipe A, Vicente R, Villalonga N, Roura-Ferrer M, Martinez-Marmol R, Sole L, et al. Potassium channels: new targets in cancer therapy. Cancer Detect Prev. 2006;30:375–85.PubMedCrossRef

Nilius B, Schwarz G, Droogmans G. Control of intracellular calcium by membrane potential in human melanoma cells. Am J Physiol. 1993;265(6 Pt 1):1501–10.

Pancrazio JJ, Tabbara IA, Kim YI. Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. Anticancer Res. 1993;13:1231–4.PubMed

Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS. Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol. 1995;162:163–71.PubMedCrossRef

10.

Bayliss DA, Barrett PQ. Emerging roles for two-pore-domain potassium channels and their potential therapeutic impact. Trends Pharmacol Sci. 2008;29:566–75.PubMedCrossRef

11.

Ketchum KA, Joiner WJ, Sellers AJ, Kaczmarek LK, Goldstein SA. A new family of outwardly rectifying potassium channel proteins with two pore domains in tandem. Nature. 1995;376:690–5.PubMedCrossRef

12.

Honore E. The neuronal background K2P channels: focus on TREK1. Nat Rev Neurosci. 2007;8:251–61.PubMedCrossRef

13.

Patel AJ, Lazdunski M, Honore E. Lipid and mechano-gated 2P domain K(+) channels. Curr Opin Cell Biol. 2001;13:422–8.PubMedCrossRef

14.

Marklund L, Henriksson R, Grankvist K. Cisplatin-induced apoptosis of mesothelioma cells is affected by potassium ion flux modulator amphotericin B and bumetanide. Int J Cancer. 2001;93:577–83.PubMedCrossRef

15.

Shepherd TG, Campbell EL, Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc. 2007;1:2643–9.CrossRef

16.

Asher V, Khan R, Warren A, Shaw R, Schalkwyk GV, Bali A, et al. The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol. 2010;5:78.PubMedCrossRef

17.

Asher V, Warren A, Shaw R, Sowter H, Bali A, Khan R. The role of Eag and HERG channels in cell proliferation and apoptotic cell death in SK-OV-3 ovarian cancer cell line. Cancer Cell Int. 2011;11:6.PubMedCrossRef

18.

Pei L, Wiser O, Slavin A, Mu D, Powers S, Jan LY, et al. Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proc Natl Acad Sci USA. 2003;100:7803–7.PubMedCrossRef

19.

Wang Z. Roles of K+ channels in regulating tumour cell proliferation and apoptosis. Pflugers Arch. 2004;448:274–86.PubMedCrossRef

20.

Patel AJ, Lazdunski M. The 2P-domain K+ channels: role in apoptosis and tumorigenesis. Pflugers Arch. 2004;448:261–73.PubMedCrossRef

21.

Lepple-Wienhues A, Berweck S, Bohmig M, Leo CP, Meyling B, Garbe C, et al. K+ channels and the intracellular calcium signal in human melanoma cell proliferation. J Membr Biol. 1996;151:149–57.PubMedCrossRef

22.

Nilius B, Wohlrab W. Potassium channels and regulation of proliferation of human melanoma cells. J Physiol. 1992;445:537–48.PubMed

23.

Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010;17:6–11.PubMed

24.

Gansler TS, Hardman W 3rd, Hunt DA, Schaffel S, Hennigar RA. Increased expression of fatty acid synthase (OA-519) in ovarian neoplasms predicts shorter survival. Hum Pathol. 1997;28:686–92.PubMedCrossRef

25.

Fujita T, Miyamoto S, Onoyama I, Sonoda K, Mekada E, Nakano H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. Cancer Lett. 2003;192:161–9.PubMedCrossRef

26.

Harguindey S, Orive G. Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin—one single nature. Biochim Biophys Acta. 2005;1756:1–24.PubMed

27.

Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 2010;3:11.PubMedCrossRef

28.

Enyeart JA, Liu H, Enyeart JJ. Curcumin inhibits bTREK-1 K+ channels and stimulates cortisol secretion from adrenocortical cells. Biochem Biophys Res Commun. 2008;370:623–8.PubMedCrossRef

29.

Park KJ, Baker SA, Cho SY, Sanders KM, Koh SD. Sulfur-containing amino acids block stretch-dependent K+ channels and nitrergic responses in the murine colon. Br J Pharmacol. 2005;144:1126–37.PubMedCrossRef

30.

Ditscheid B, Funfstuck R, Busch M, Schubert R, Gerth J, Jahreis G. Effect of l-methionine supplementation on plasma homocysteine and other free amino acids: a placebo-controlled double-blind cross-over study. Eur J Clin Nutr. 2005;59:768–75.PubMedCrossRef

Titel: Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer
verfasst von: A. Innamaa
L. Jackson
V. Asher
G. van Schalkwyk
A. Warren
A. Keightley
D. Hay
A. Bali
H. Sowter
R. Khan
Publikationsdatum: 01.11.2013
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 11/2013
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-013-1022-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2013

Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis

Early volumetric change and treatment outcome of metastatic brain tumors after external beam radiotherapy: differential radiotherapy for brain metastasis

Prognostic significance of annexin II expression in non-small cell lung cancer

Zoledronic acid in genitourinary cancer

The application of ultrasonic harmonic scalpel in the radical surgery of gastric cancer

Up-regulation of nuclear receptor coactivator amplified in breast cancer-1 in papillary thyroid carcinoma correlates with lymph node metastasis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie